比伐卢定在体外膜肺氧合中的应用进展

Research advances of bivalirudin in extracorporeal membrane oxygenation

体外膜肺氧合(extracorporeal membrane oxygenation,ECMO)过程中常规使用的抗凝剂普通肝素(UFH)由于容易引起出血、血小板减少、肝素抵抗等弊端颇具争议,而比伐卢定作为一种人工合成的直接凝血酶抑制剂(DTI),具有特异性强、半衰期短、安全性高等特点,与UFH相比具有一些潜在优势。本文通过综述比伐卢定在ECMO中的研究进展,为ECMO患者的抗凝策略提供更多参考依据。

For many years,the conventional anticoagulant unfractionated heparin(UFH)used in the process of extracorporeal membrane oxygenation(ECMO)has been controversial due to its drawbacks such as easy bleeding,thrombocytopenia and heparin resistance.As a synthetic direct thrombin inhibitor(DTI),bivalirudin has strong specificity,short half-life and high safety,which has some potential advantages compared with UFH.In this paper,the research progress of bivalirudin in ECMO was reviewed to provide more references for anticoagulation in ECMO patients.